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Abstract
Background: Target organ damage (mainly cardiac and renal damage) is easy to evaluate in outpatient clinics and
offers valuable information about patient's cardiovascular risk. The purpose of this study was to evaluate, using
simple methods, the prevalence of cardiac and renal damage and its relationship to the presence of established
cardiovascular disease (CVD), in patients with hypertension (HT) and type 2 diabetes mellitus (DM).
Methods: The RICARHD study is a multicentre, cross-sectional study made by 293 investigators in Nephrology
and Internal Medicine Spanish outpatient clinics, and included patients aged 55 years or more with HT and type
2 DM with more than six months of diagnosis. Demographic, clinical and biochemical data, and CVD were
collected from the clinical records. Cardiac damage was defined by the presence of electrocardiographic left
ventricular hypertrophy (ECG-LVH), and renal damage by a calculated glomerular filtration rate (GFR) of <60 ml/
min/1.73 m2, and/or the presence of an albumin/creatinine ratio ≥ 30 mg/g; or an urinary albumin excretion (UAE)
≥ 30 mg/24 hours.
Results: 2339 patients (mean age 68.9 years, 48.2% females, 51.3% with established CVD) were included. ECG-
LVH was present in 22.9% of the sample, GFR <60 ml/min/1.73 m2 in 45.1%, and abnormal UAE in 58.7%.
Compared with the reference patients (those without neither cardiac nor renal damage), patients with ECG-LVH
alone (OR 2.20, [95%CI 1.43–3.38]), or kidney damage alone (OR 1.41, [1.13–1.75]) showed an increased
prevalence of CVD. The presence of both ECG-LVH and renal damage was associated with the higher prevalence
(OR 3.12, [2.33–4.19]). After stratifying by gender, this relationship was present for both, men and women.
Conclusion: In patients with HT and type 2 DM, ECG-LVH or renal damage, evaluated using simple methods,
are associated with an increased prevalence of established CVD. The simultaneous presence of both cardiac and
renal damage was associated to the higher prevalence of CVD, affording complementary information. A
systematic assessment of cardiac and renal damage complements the risk assessment of these patients with HT
and type 2 DM.
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Background
The presence of diabetes mellitus (DM) increases the risk
of any form of cardiovascular disease (CVD) and of death
in hypertensive patients [1]. In the natural course of arte-
rial hypertension (HT) it moreover has been seen that the
development of type 2 DM during treatment multiplies
the risk of cardiovascular complications over the middle
term [2].
In the outpatient setting, the detection of silent cardiac
damage (mainly left ventricular hypertrophy [LVH]) [3,4],
or of renal disease (pathological urinary albumin excre-
tion [UAE] [5,6] or diminished glomerular filtration rate
[GFR] [7,8]) in patients with HT and/or DM, defines a
subgroup in whom cardiovascular risk is even greater. The
detection of such target organ damage is simple in daily
clinical practice, based on the electrocardiogram (ECG)
and assessment of kidney function and UAE. Specifically,
in patients with HT and DM, this identifies patients at very
high cardiovascular risk. In the LIFE study, on patients
with HT and electrocardiographic left ventricular hyper-
trophy (ECG-LVH), mortality during a follow-up period
of 5 years was 14% [9], figure that was even greater among
patients with elevated UAE [10].
The implication of target organ damage in the appearance
of cardiovascular complications, and the possibility of
adopting treatments to induce regression of such damage
– with improvements in patient prognosis in some cases
–, make it necessary to carefully assess silent organ dam-
age. Epidemiological studies conducted in our setting and
involving hypertensive subjects have shown a prevalence
of ECG-LVH of 10–20% [11-13], with a prevalence of kid-
ney damage of 20–30% [14]. However, no studies to date
have evaluated in Spain the prevalence of target organ
damage based on simple methods (basically ECG and
blood and urine tests), and its impact upon the prevalence
of established CVD in patients with HT and type 2 DM.
The main objective of the RICARHD study (Cardiovascu-
lar risk in patients with arterial hypertension and type 2
diabetes) was to evaluate the prevalence of hypertensive
cardiac and renal damage using the methods commonly
used in outpatient clinics, and its relationship to the pres-
ence of established CVD, in a population of patients with
HT and type 2DM.
Patients and methods
The RICARHD study was an epidemiological, multicentre,
cross-sectional study conducted by 293 physicians spe-
cialized in Internal Medicine or Nephrology, in outpatient
consulting offices. The study was approved by an inde-
pendent Clinical Research Ethics Committee. The data
collection period was between October and December
2005. Each investigator recorded information of 10
patients with HT and type 2 DM. In order to reduce selec-
tion bias, inclusion was requested of the first two or three
programmed patients during 4–5 consecutive days. The
study protocol was explained to the patients, and written
informed consent was obtained.
The study comprised patients aged 55 years or older, with
a diagnosis of HT and type 2 DM – both disorders having
been present for more than 6 months. The presence of
nephropathy not caused by DM or HT, and patient refusal
to take part in the study were considered exclusion crite-
ria. The clinical data were obtained from the patient his-
tory, while the biochemical parameters were recorded
from laboratory testing in the three months prior to con-
sultation (or in the days after consultation if no such prior
testing proved available). Blood pressure (BP) recordings
were made twice, under baseline conditions, and spaced
one minute apart. Patient smoking or the consumption of
coffee or other stimulants was not allowed before these
measurements were obtained.
Evaluation of the main objective
The main objective of the study was to evaluate the prev-
alence of cardiac [LVH] and renal damage, based on the
ECG and laboratory tests, in patients diagnosed with HT
and type 2DM, and its relationship to the presence of
established CVD.
ECG-LVH was diagnosed based on the voltage criteria of
Cornell [15], and of Sokolow-Lyon [16]. The presence of
ECG-LVH was accepted if the patient met: a) the voltage
criterion of Cornell (sum of the R-wave on lead aVL + S-
wave on V3> 20 mm in women, or >28 mm in males); or
b) the voltage criterion of Sokolow-Lyon (sum of the S-
wave on V1+ R-wave on leads V5 or V6>38 mm); or c) the
patient history specified the presence of ECG-LVH based
on any other criterion. Kidney damage was evaluated by
conventional laboratory tests. GRF was calculated auto-
matically from serum creatinine using the simplified
Modification of Diet in Renal disease (MDRD) equation
[17]. Urine testing was also carried out to calculate the
UAE, by the albumin/creatinine (A/C) ratio or the 24-
hour UAE. Kidney damage was considered if: a) the calcu-
lated GFR was <60 ml/min/1.73 m2; or b) the patient pre-
sented an A/C ratio of ≥ 3.5 mg/mmol (30 mg/g); or c) the
patient presented an UAE ≥ 30 mg/24 hours.
The presence of established CVD was defined according to
the patient's clinical records, and included myocardial inf-
arction, angina, heart failure, peripheral vascular disease
and stroke.
Statistical analysis
The sample size was calculated according to the main
objective of the study and based on the expected preva-
lence of heart and kidney damage. For an expected preva-Cardiovascular Diabetology 2006, 5:23 http://www.cardiab.com/content/5/1/23
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lence of <10%, a sample size of 2401 hypertensive
diabetic patients was estimated for a 95% confidence
interval (CI) and an error of 1.2%. The sample was
increased 4% to cover data losses, yielding a definitive size
of 2500 patients.
Qualitative variables are shown with their frequency dis-
tribution. Quantitative variables are summarized by their
mean, standard deviation (SD), range and percentiles.
Asymmetric variables were described by the median and
interquartile range (p25–p75). Association between qual-
itative variables was evaluated using the chi-square or the
Fisher exact tests. The behavior of quantitative variables
was analyzed for each of the independent variables using
the Mann-Whitney U-test or median test.
A multivariable logistic regression model was made to
account for the association of the study variables to the
prevalence of established CVD. The odds ratios (OR) and
corresponding 95% CI are presented.
Variable distribution was verified in all cases as compared
with the theoretical models, and the hypothesis of homo-
geneity of variances was tested. In all hypothesis testing,
the null hypothesis was rejected with a type I error or an
alpha error <0.05. The SPSS 11.0 statistical package was
used throughout.
Results
Descriptive data
Information was collected on 2466 patients, a total of
127(5.2%) being excluded from the analysis because they
failed to meet some inclusion criterion or lacked some
essential information. The final sample comprised 2339
patients (mean age 68.9 years [SD 10.8, range 55–98],
48.2% females). The mean body mass index (BMI) was
29.9 kg/m2(SD 7.8). 42.9% had obesity (BMI ≥ 30 kg/
m2), and 11.6% were smokers. Some antecedent of CVD
was recorded in 51.3% of the patients while 14.6% had a
history of atrial fibrillation. The mean BP was 148.3/80.4
mmHg (SD 15.1/11.5), and only 15% showed BP < 130/
80 mmHg. The characteristics of males and females are
summarized in Table 1.
Target organ damage
ECG-LVH was present in 22.9% of the patients, (22.2% of
women and 23.7% of males, p = NS). GFR <60 ml/min/
1.73 m2 was documented in 45.1% (52.7% of women and
37.9% of males, p < 0.001). Information on UAE was
available in 1887 patients – abnormal values (A/C ratio ≥
3.5 mg/mmol [30 mg/g], or UAE ≥ 30 mg/24 hours) being
recorded in 58.7% of the subjects (52.8% of women and
64.2% of males, p < 0.001).
Cardiac and renal damage, and the prevalence of 
cardiovascular disease
To assess the relationship between the presence of cardiac
and/or renal damage and of established CVD, the study
population was divided into four groups: patients without
Table 1: Characteristics of the patients included in the RICARHD study.
Total Males Females
Mean (SD) Mean (SD) Mean (SD)
Age (years)* 68.7 (10.8) 67.1 (10.3) 70.3 (11.0)
BMI (kg/m2) 29.9 (7.8) 29.4 (9.2) 30.4 (5.8)
Abdominal perimeter (cm)* 100.4 (14.2) 102.2 (13.3) 98.4 (14.9)
Systolic blood pressure (mmHg)* 148.3 (15.1) 144.0 (17.9) 152.8 (21.6)
Diastolic blood pressure (mmHg) 80.4 (11.5) 80.0 (11.2) 80.8 (11.9)
%%%
BMI (kg/m2) classification <25 15.8% 14.9% 16,8%
25–29.9 41.3% 47.3% 34,8%
≥ 30 42.9% 37.8% 48,4%
Moderate-severe alcohol consumption* 10.0% 17.5% 1.8%
Smoking* 11.6% 17.3% 5.5%
Hypercholesterolemia 64.6% 64.2% 64.9%
BP control 15.0% 15.3% 14.6%
Glomerular filtrate <60 ml/min/1.73 m2* 45.1% 37.9% 52.7%
Left ventricle hypertrophy on ECG 22.9% 23.7% 22.2%
Established cardiovascular disease**, * 51.3% 55.1% 47.2%
Atrial fibrillation* 14.6% 12.5% 16.9%
*p < 0.05 for the difference between sexes. BMI: body mass index; ECG: electrocardiogram.
** Includes myocardial infarction, chest pain, heart failure, stroke and intermittent claudicationCardiovascular Diabetology 2006, 5:23 http://www.cardiab.com/content/5/1/23
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cardiac or renal lesions (28.6%); patients with ECG-LVH
but no kidney damage (5.4%); patients with kidney dam-
age and no ECG-LVH (48.4%); and patients with both
ECG-LVH and renal damage (17.6%). Figure 1 shows the
frequency distributions for the global population and by
gender.
The demographic characteristics of the four groups are
shown in Table 2. Compared with the patients without
ECG-LVH and without kidney damage, those with ECG-
LVH showed (p < 0.05) higher mean systolic and diastolic
BP values and a greater frequency of established CVD and
atrial fibrillation. The patients with kidney damage were
older, showed higher systolic BP and had a greater fre-
quency of established CVD and atrial fibrillation (p <
0.05). Finally, those with heart and kidney damage were
older, showed higher mean systolic BP and had a greater
frequency of established CVD and atrial fibrillation,
smoking and alcohol consumption, and hypercholestero-
lemia (p < 0.05).
The prevalence of the different manifestations of CVD,
stratified by the presence of absence of ECG-LVH and/or
kidney damage, is reported in Table 3. Compared with the
patients with no cardiac or kidney damage, the subjects
with kidney or cardiac damage showed a higher preva-
lence of any type of CVD (p < 0.001). The highest preva-
lence of any CVD was present in those with both ECG-
LVH and kidney damage.
Multivariate analysis
To evaluate the impact of ECG-LVH and kidney damage
upon the prevalence of established CVD, a multivariate
model was constructed that included age, sex, BMI, mod-
erate-severe alcohol consumption, smoking, hypercholes-
terolemia and BP.
Compared with the reference patients (no ECG-LVH and
no kidney damage), the presence of ECG-LVH was associ-
ated with a 2-fold increased prevalence of established
CVD (adjusted OR 2.20, 95%CI 1.43–3.38), while the
presence of kidney damage alone was associated with a
41% greater prevalence (adjusted OR 1.41, 95%CI 1.13–
1.75). The concomitant presence of both, ECG-LVH and
renal damage was associated with a 3-fold greater preva-
lence (adjusted OR 3.12, 95%CI 2.33–4.19) of estab-
lished CVD. This relationship was shown for the whole
population, and also after stratifying by gender (table 4).
Discussion
The main findings of the RICARHD study were the follow-
ing: 1) The presence of target organ damage (ECG-LVH,
renal dysfunction, or abnormal UAE) is frequent in this
group of patients with HT and type 2 DM seen in special-
ized clinics; 2) Such lesions are related to an increased
prevalence of established CVD; and 3) The concomitant
presence of cardiac and renal damage is associated with an
even higher prevalence of cardiovascular complications.
Thus, the integral evaluation of both types of lesion
affords complementary information. The study was car-
ried out in Internal Medicine and Nephrology outpatient
clinics, and the conclusions drawn are applicable to the
profile of the patients seen in such settings.
The prevalence of ECG-LVH was nearly 23%, based on
simple voltage criteria, and was similar in both males and
females. This prevalence may be slightly greater than
expected, since the study was conducted in specialized
centers. In other study conducted in the out-hospital set-
ting in patients with DM (85% with concomitant HT), the
prevalence of ECG-LVH based on the Cornell product was
17.1% [18]. Echocardiographic studies in turn report
prevalences between 43% in the study of Sato et al. in
patients with normal UAE not taking antihypertensive
treatment [19] and 71% in the study of Dawson et al.,
conducted in the hospital setting [20].
In any case, LVH tends to be more prevalent in hyperten-
sive diabetic patients than in non-diabetics [13], as is the
case in patients with the metabolic syndrome [21]. Meta-
bolic anomalies involving insulin resistance and hyperin-
sulinemia could favor the appearance of LVH
independently of HT. At experimental level, insulin exerts
trophic effects in animal models [22], while a number of
human studies have reported a relationship among high
insulin levels, insulin resistance and left ventricle mass
[23-25]. In addition, insulin induces sodium retention at
Distribution of the study population according to cardiac  and/or renal damage Figure 1
Distribution of the study population according to cardiac 
and/or renal damage. ECG-LVH: electrocardiographic left 
ventricular hypertrophy
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kidney level [26], which may also contribute to the devel-
opment of LVH.
A total of 45.1% of the patients showed GFR <60 ml/min/
1.73 m2. GFR was calculated using the simplified MDRD
equation [17]. Although this equation may underestimate
GFR by up to 29% in healthy subjects, this figure drops to
only 6% in patients with genuinely reduced GFR [27], and
is moreover the most widely used equation to calculate
GRF. GFR decreases with increasing age, and the percent-
age of patients with diminished GFR recorded in our
series is not surprising, moreover considering that HT and
DM are independent risk factors for renal derangement.
The greater prevalence of impaired kidney function
among women has already been reported in other studies
in our setting [28] and in other countries [29,30], and is a
consequence of the correction included in the equation
for the decrease in muscle mass in women.
The prevalence of pathological UAE was very high in our
series (58.7%). This may be conditioned by the fact that
some patients were evaluated in Nephrology clinics.
Microalbuminuria is predictive of posterior impaired
renal function [31], and cross-sectional studies also have
revealed an independent relationship between insulin
resistance and microalbuminuria [32]. The relationship
between diminished GFR and the risk of cardiovascular
complications and death has also been observed in differ-
ent follow-up studies [7,8].
The most useful finding in our study was the relationship
between silent target organ damage and established CVD.
The prevalence of established CVD was twice as great in
patients with ECG-LVH of either sex, between 30–60%
greater in patients with kidney damage versus patients
without ECG-LVH or kidney damage, and ever greater
(three-fold) in those with both kidney and cardiac dam-
Table 3: Prevalence of established cardiovascular disease according to the presence of cardiac and/or renal damage.
No ECG-LVH and no renal 
damage
(28.6%)
(Group A)
ECG-LVH only
(5.4%)
(Group B)
Renal damage only
(48.4%)
(Group C)
ECG-LVH and renal 
damage
(17.6%)
(Group D)
Cardiovascular disease (any), % 37.7% 58.9%A 51.4%A 70.6%A, C
Angina, % 12.4% 19.7%A 14.7% 22.0%A, C
Myocardial infarction, % 13.1% 25.4% 17.5% 28.2%A, C
Heart failure, % 10.3% 23.8%A 20.6%A 33.8%A
Peripheral vascular disease, % 6.1% 10.8% 14.9%A 28.0%A, B, C
Stroke, % 11.9% 13.8% 18.2%A 23.7%A
Atrial fibrillation, % 7.8% 18.0%A 15.3%A 22.5%A, C
ECG-LVH: electrocardiographic left ventricular hypertrophy. Superscripts (A, B, C, D) mean p < 0.05 compared to the indicated group.
Table 2: Characteristics according to the presence or absence of cardiac and renal damage.
No ECG-LVH and no renal 
damage
(28.6%)
(Group A)
ECG-LVH only
(5.4%)
(Group B)
Renal damage only
(48.4%)
(Group C)
ECG-LVH and renal 
damage
(17.6%)
(Group D)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (years) 66.2(10.6) 67.4(12.6) 69.8(10.6)A 69.9(10.3)A
Systolic blood pressure (mmHg) 142.9(17.4) 149.8(21.7) 151.1(21.2) 148.1(19.3)
Diastolic blood pressure
(mmHg)
80.6(10.4) 83.1(12.1)C 79.6(11.8) 81.3(12.5)
BMI (kg/m2) 29.9 30.2 29.7 29.6
%%%%
Females 46.5% 48.0% 50.1% 46.1%
BMI ≥ 30 kg/m2 41.6% 48.8% 43.4% 41.9%
Moderate-severe alcohol
consumption
9.8% 9.7% 8.2% 15.0%A, B, C, D
Smoking 10.3% 10.5% 10.5% 16.0%A, B, C, D
Hypercholesterolemia 62.1% 66.4%A 64.7% 70.0%A, C
BP control 14.2% 13.8% 17.0%D 11.2%
Established cardiovascular
disease*
37.7% 58.9%A 51.4%A 70.6%A, C
Atrial fibrillation 7.8% 18.0%A 15.3%A 22.5%A, C
See text for significance. BMI: body mass index; BP: blood pressure. *Includes myocardial infarction, angina, heart failure, stroke and peripheral 
vascular disease. ECG-LVH: electrocardiographic left ventricular hypertrophy. Superscripts (A, B, C, D) mean p < 0.05 compared to the indicated 
group.Cardiovascular Diabetology 2006, 5:23 http://www.cardiab.com/content/5/1/23
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age. This suggests that careful evaluation of these organs
can improve patient risk assessment, and that the presence
of kidney damage adds information to the presence of
ECG-LVH and vice versa.
The data afforded by follow-up surveys and by cross-sec-
tional studies thus support the need for correct assessment
of damage to both target organs in patients with HT and
DM, in order to define the cardiovascular risk and man-
agement strategy. The 2003 European Society of Cardiol-
ogy/European Society of Hypertension Guidelines for the
Management of Arterial Hypertension consider both, dia-
betes mellitus and target organ damage, as situations asso-
ciated to a high 10-year cardiovascular risk (20–30%)
even in subjects with high-normal BP [33]. This and other
studies as the LIFE diabetes substudy address the question
of if these diabetic hypertensive patients with target organ
damage should fall into the very-high risk category (esti-
mated ten-year risk of CVD over 30%). In the LIFE study,
the mortality rate after 4.8 years of follow-up (half the fol-
low-up that that used for the estimation in the Guide-
lines) was 14% for the subgroup of diabetic patients with
HT and ECG-LVH [9], and 20,3% suffered a cardiovascu-
lar complication (cardiovascular death, myocardial infarc-
tion or stroke). Moreover, the higher risk was for those
with UAE >16.9 mg/mmol (approximately equivalent to
150 mg/g), in whom mortality after 4.8 years was nearly
20%, and the incidence of cardiovascular complications
was 26.4% [10].
In diabetic patients a BP control target of under 130/80
mmHg is accepted [33-35], and blocking of the rennin-
angiotensin system is recommendable when kidney dam-
age or ECG-LVH is detected. Different studies have shown
that not only is such organ damage predictive of cardio-
vascular complications, but – more importantly – the
regression of such lesions reduces the incidence of cardio-
vascular complications over the middle term. In the 1195
patients with HT, DM and ECG-LVH of the LIFE DM sub-
study [9], treatment with losartan (plus hydrochlorothi-
azide in most cases) reduced mortality by 40% versus
treatment with atenolol (plus hydrochlorothiazide in
most cases) and the greater reduction of microalbuminu-
ria after one year of treatment was related to posterior
reduction of the cardiovascular complications and in
mortality [36]. A number of studies have also shown that
in patients with HT and LVH, hypertrophy regression as
demonstrated by both ECG [37,38] and echocardiogra-
phy [39,40] is associated with an improved cardiovascular
prognosis and that, moreover, the regression of both dis-
orders (microalbuminuria and LVH) may improve the
prognosis even more than regression of only one of the
lesions [41]. Therefore, therapy in these patients should
aim not only to control BP but also to induce regression
of LVH and to reduce UAE.
Our study presents two major limitations: its cross-sec-
tional nature and the setting in which it was carried out.
The cross-sectional design only allows us to establish asso-
ciations, without reliably defining the underlying cause-
effect relationship. The important of some cardiovascular
diseases involving high mortality, such as stroke, may be
underestimated. The selection of Internal Medicine and
Nephrology clinics for conducting the study means that
the observed prevalences do not reflect the global popula-
tion of hypertensive patients with type 2 DM. In fact, the
prevalences of established CVD in this sample, as well as
of renal damage, were extremely high. These high preva-
lences may be due not only to the setting in which the
study was conducted but also because the selection of
patients was not done at random: they were consecutively
included, and this could have favored the inclusion of
more sick patients (patients with established CVD),
because they are usually more closely followed-up and
attend the outpatient clinics more frequently. In this
sense, the results of our study should apply only to this
population and not to the universe of hypertensive type 2
diabetic patients. Nevertheless, the conclusions drawn in
terms of the relationship between target organ damage
and CVD are valid, and the size of the sample and the
multicenter nature of the study offer a very reliable assess-
ment of the population seen by such specialists.
Table 4: Odds ratio of prevalence of cardiovascular disease, related to cardiac and/or renal damage.
OR (95%CI) for cardiovascular disease
Global* Male Female
No ECG-LVH or kidney damage (reference)** 1 1 1
Only ECG-LVH 2.20 (1.43–3.38) p < 0.001 2.06 (1.13–3.78) p = 0.018 2.39 (1.29–4.44) p = 0.006
Only kidney damage 1.41 (1.13–1.75) p = 0.002 1.61 (1.19–2.18) p = 0.002 1.27 (0.92–1.75) p = 0.148
ECG-LVH and kidney damage 3.12 (2.33–4.19) p < 0.001 2.92 (1.95–4.39) p < 0.001 3.50 (2.28–5.37) p < 0.001
Adjusted for age, body mass index, sedentarism, hypercholesterolemia, blood pressure control, smoking, alcohol consumption, atrial fibrillation and 
*sex. OR: odds ratio; ECG-LVH: electrocardiographic left ventricular hypertrophy. **Reference group.Cardiovascular Diabetology 2006, 5:23 http://www.cardiab.com/content/5/1/23
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Conclusion
In conclusion, the prevalence ECG-LVH and of renal dam-
age, diagnosed by simple methods, in this population of
hypertensive patients with type 2 DM, is high, and is asso-
ciated with an increased prevalence of established CVD.
Moreover, each lesion is independently related to CVD –
the simultaneous presence of both lesions affording com-
plementary information. The methods used to evaluate
these lesions are very simple and inexpensive, and their
careful application may help to improve the evaluation
and to establish therapeutic objectives and strategies in
these patients with such important cardiovascular risk.
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